Drugs / IPG1094
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07679113 | Jul 2026 → Jan 2027 expected | — | Nanjing Immunophage Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05112159 | Sep 2021 → Jul 2022 | — | Nanjing Immunophage Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06212076 | Jul 2024 → Jul 2027 expected | cancer | Nanjing Immunophage Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPG1094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05112159 ↗ |
| Action | Inhibit | “An inhibitor of macrophage migration inhibitory factor (MIF)” NCT06212076 ↗ |
| Route | Oral | “orally administered IPG1094” NCT05112159 ↗ |
| Target | MIF | “An inhibitor of macrophage migration inhibitory factor (MIF)” NCT06212076 ↗ |